VivoSim Labs, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
VivoSim Labs, Inc. (VIVS) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $342.00 thousand as of 2026-03-31, per its 10-K filed 2026-07-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-07-14
- 2026-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $342.00K.
- 2025-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $336.00K.
- 2024-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $315.00K.
- 2023-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $755.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2026-03-31 | $342.00K 10-K · filed 2026-07-14 |
| 2025-03-31 | $336.00K 10-K · filed 2026-07-14 |
| 2024-03-31 | $315.00K 10-K · filed 2025-06-05 |
| 2023-03-31 | $755.00K 10-K · filed 2024-05-31 |
| 2022-03-31 | $554.00K 10-K · filed 2023-07-14 |
| 2021-03-31 | $2.43M 10-K · filed 2022-06-10 |
| 2020-03-31 | $3.90M 10-K · filed 2021-06-15 |
| 2019-03-31 | $3.94M 10-K · filed 2020-05-28 |
| 2018-03-31 | $3.75M 10-K · filed 2019-06-03 |
| 2017-03-31 | $6.72M 10-K · filed 2018-05-31 |
| 2016-03-31 | $5.58M 10-K · filed 2018-05-31 |
| 2015-03-31 | $3.46M 10-K · filed 2016-06-09 |
| 2014-03-31 | $1.94M 10-K · filed 2015-06-09 |
| 2013-03-31 | $743.00K 10-K · filed 2014-06-10 |
| 2012-12-31 | $562.00K 10-K · filed 2014-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |